[
  {
    "question": "Scenario of ALS, Dx?",
    "option_a": "nalysis clarifies that there is no single diagnostic test for ALS. Options that might suggest reliance on isolated investigations like MRI or genetic tests are inadequate. The correct answer",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that affects both upper and lower motor neurons. Its diagnosis is based on a constellation of clinical signs including muscle weakness, spasticity, atrophy, and fasciculations rather than on a single definitive test. ALS involves degeneration of motor neurons in the motor cortex, brainstem, and spinal cord. Proposed mechanisms include glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, and protein misfolding (e.g., SOD1 mutations). Despite intense research, no definitive biomarker has been established, making the diagnosis primarily clinical and electrophysiologic. Patients typically present with asymmetrical limb weakness, mixed UMN (e.g., spasticity, hyperreflexia) and LMN signs (e.g., muscle atrophy, fasciculations), and bulbar symptoms such as dysarthria or dysphagia. These features, when found in multiple body regions, strongly suggest ALS. Diagnosis relies on established criteria (e.g., El Escorial criteria) and is supported by electromyography (EMG) demonstrating denervation and fasciculation potentials. Differential diagnoses include multifocal motor neuropathy (which may be immune-mediated), cervical spondylotic myelopathy, and primary lateral sclerosis. MRI and genetic testing, though useful for exclusion or further stratification, do not serve as confirmatory tests. Current guidelines recommend medications such as riluzole and edaravone as first\u2010line therapies to modestly slow disease progression. Multidisciplinary supportive care (physical therapy, respiratory support, nutritional interventions) is crucial. In pregnancy and lactation, the risk\u2013benefit profile of these agents must be individually evaluated, with careful consultation between neurology, obstetrics, and pharmacology specialists. The option analysis clarifies that there is no single diagnostic test for ALS. Options that might suggest reliance on isolated investigations like MRI or genetic tests are inadequate. The correct answer \u2013 indicated as \u201cUnknown\u201d (which in this question context corresponds to option B) \u2013 correctly reflects that the diagnostic confirmation of ALS is clinical and electrophysiological, not dependent on any definitive biomarker. 1) ALS requires evidence of both upper and lower motor neuron involvement in multiple regions. 2) EMG is a key supportive tool but does not serve as a stand-alone diagnostic test. 3) Despite ongoing research, no definitive biomarker exists in routine clinical practice. Recent studies continue to explore the utility of serum and CSF biomarkers (like neurofilament light chain levels), but the gold standard remains clinical evaluation backed by EMG findings. Current guidelines still emphasize the importance of a comprehensive clinical approach amidst evolving research.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Patient had bariatric surgery developed weakness and large fiber neuropathy, normal B12 and MMA",
    "option_a": "Copper",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "After bariatric surgery, patients are at risk for nutritional deficiencies due to altered gastrointestinal anatomy, which can lead to conditions such as copper deficiency neuropathy. Bariatric surgery can impair the absorption of micronutrients, including copper, due to bypassed segments of the gastrointestinal tract and reduced gastric acid secretion. Copper is essential for proper neurological function and myelin formation; deficiency leads to demyelination and axonal degeneration, particularly affecting large myelinated fibers. Patients with copper deficiency may present with symptoms similar to B12 deficiency neuropathy, including peripheral neuropathy and myelopathy. In the scenario described, the normal B12 and methylmalonic acid (MMA) levels help rule out B12 deficiency, making copper deficiency the most likely cause of the large fiber neuropathy and weakness. Differentials include vitamin B12 deficiency, zinc toxicity (which can also cause copper depletion), and other micronutrient deficiencies. A thorough nutritional panel including serum copper and ceruloplasmin levels helps in making the correct diagnosis. First-line management involves copper supplementation, either orally for mild/moderate cases or intravenously for severe deficiencies. Nutritional counseling and monitoring of other trace elements are essential. In pregnancy and lactation, copper supplementation is safe and necessary since copper is vital for fetal development; however, dosing should be carefully monitored to avoid toxicity. Option A, which indicates copper deficiency as the etiology, is correct. Other potential options (if provided) would likely include vitamin deficiencies like B12, which have been ruled out by normal lab findings. This focused evaluation supports copper deficiency as the primary diagnosis. 1) Copper deficiency can clinically mimic B12 deficiency neuropathy despite normal B12 levels. 2) A history of bariatric surgery should prompt evaluation for trace metal deficiencies. 3) Early copper supplementation can lead to significant improvement in neurological symptoms. Emerging research supports routine monitoring of trace elements following bariatric surgery. Recent guidelines emphasize the importance of screening for copper deficiency in patients with unexplained neuropathies after gastrointestinal surgeries, highlighting its reversibility with timely intervention.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of LHON (diagnosis not mentioned), what you will do by knowing the complications of this condition?",
    "option_a": "ECG",
    "option_b": "Renal US",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Leber\u2019s Hereditary Optic Neuropathy (LHON) is a mitochondrial disorder characterized primarily by painless, subacute vision loss. However, its systemic mitochondrial dysfunction can occasionally affect other organs, including the heart. LHON results from mutations in mitochondrial DNA that impair oxidative phosphorylation. While the hallmark is degeneration of retinal ganglion cells, some patients may have associated cardiac conduction abnormalities due to the involvement of mitochondria in cardiac tissue, as observed in other mitochondrial disorders. Patients with LHON typically present with central vision loss, most often in young males. Given the mitochondrial basis of the disorder, some patients may also develop cardiac issues, which justify further evaluation such as an electrocardiogram (ECG). The diagnostic workup for LHON includes an ophthalmologic examination with fundoscopic evaluation and genetic testing for mitochondrial mutations. Differential diagnoses include optic neuritis, toxic/nutritional optic neuropathies, and other hereditary optic neuropathies. In patients with LHON, a cardiac evaluation (via ECG) is warranted if there is suspicion of conduction abnormalities. Management is largely supportive. Some guidelines advocate for idebenone in Europe, though its benefit is modest. Standard care includes avoiding smoking and other mitochondrial toxins. Given the potential cardiac associations, an ECG is recommended as part of the evaluation, especially if there are any cardiac symptoms. In pregnant or lactating women, medication use requires caution and interdisciplinary consultation, and non-pharmacologic management is emphasized. Option A, obtaining an ECG, is appropriate because it screens for possible cardiac conduction defects, which have been reported in some LHON patients with mitochondrial disorders. Option B (renal ultrasound) does not correlate with the recognized complications of LHON. 1) Although LHON primarily affects vision, its mitochondrial nature may predispose patients to systemic manifestations including cardiac conduction problems. 2) An ECG is an inexpensive, non-invasive tool to evaluate for cardiac involvement. 3) Genetic counseling is essential given the maternal inheritance pattern. Recent research underscores the multi-system involvement in mitochondrial disorders like LHON. Updated guidelines suggest that, when indicated, evaluating cardiac function with an ECG can help in early identification of conduction abnormalities and guide appropriate management.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "painful neuropathy, father has stroke, what\u2019s the diagnosis?",
    "option_a": "homocystinemia",
    "option_b": "Fabry",
    "option_c": "APL",
    "option_d": "SLE",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Fabry disease is an X-linked lysosomal storage disorder due to deficiency of the enzyme alpha-galactosidase A, leading to the systemic accumulation of globotriaosylceramide. It is known to cause multisystemic symptoms including neuropathic pain and an increased risk of cerebrovascular events such as strokes. The deficient activity of alpha-galactosidase A results in the progressive deposition of glycosphingolipids within various tissues, including vascular endothelium and peripheral nerves. This accumulation produces a characteristic painful neuropathy (often presenting as acroparesthesias) and predisposes patients to early-onset strokes, cardiac complications, and renal dysfunction. Patients with Fabry disease frequently experience burning or lancinating pain in their extremities, along with other features such as angiokeratomas, corneal verticillata, and sometimes gastrointestinal disturbances. A family history of stroke, particularly at a young age, further raises suspicion of Fabry disease as a cause of these neurologic and vascular manifestations. The workup includes measurement of alpha-galactosidase A activity (which is typically decreased in affected males) and genetic testing. Differential diagnoses include homocystinuria (which can predispose to thromboembolic events but lacks the painful neuropathy), antiphospholipid syndrome (APL, associated with thrombosis but not neuropathic pain), and systemic lupus erythematosus (SLE, which has a broader inflammatory profile). First-line management for Fabry disease involves enzyme replacement therapy (ERT) with either agalsidase beta or agalsidase alfa, which can stabilize or improve organ function. Adjunctive therapies include pain management (using anticonvulsants or antidepressants for neuropathic pain), ACE inhibitors for renal involvement, and careful cardiovascular monitoring for stroke risk. In pregnancy and lactation, the decision to continue ERT must involve a thorough risk\u2013benefit analysis with maternal\u2013fetal medicine input, but many experts advocate for continuation if the benefits outweigh the potential risks. Option B (Fabry disease) is the best answer as it explains both the presence of painful neuropathy and a family history of stroke. The other options, such as homocystinemia, antiphospholipid syndrome (APL), and SLE, do not typically present with the combination of neuropathic pain and the specific pattern of vascular involvement seen in Fabry disease. 1) Fabry disease should be considered in patients with unexplained, chronic neuropathic pain, particularly when associated with early strokes in the family. 2) Timely diagnosis and treatment with enzyme replacement therapy are crucial in preventing long-term organ damage. 3) Regular screening for cardiac, renal, and cerebrovascular complications is recommended. Recent updates in Fabry disease management emphasize early initiation of enzyme replacement therapy and a multidisciplinary approach. Ongoing trials are investigating newer modalities such as chaperone therapy and gene therapy, which hold promise for improved outcomes in the future.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Case of Crohn\u2019s disease underwent resection with fat in the stool presented with ataxia and decreased reflexes, what is the diagnosis?",
    "option_a": "Vit E",
    "option_b": "Vit b12",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This question revolves around the neurological complications associated with fat malabsorption. In patients with Crohn's disease who have undergone bowel resection, malabsorption of fat-soluble vitamins (A, D, E, and K) can occur. Vitamin E, in particular, is critical for neural protection and function. Vitamin E is a potent antioxidant that protects cell membranes from oxidative damage. Its deficiency\u2014often due to fat malabsorption after bowel resection in Crohn's disease\u2014leads to neuronal damage, especially in the posterior columns and peripheral nerves. This results in symptoms such as ataxia and decreased reflexes. Modern studies underscore that even mild chronic deficiency can lead to significant neurologic deficits. Patients with vitamin E deficiency may present with progressive ataxia, peripheral neuropathy, and decreased deep tendon reflexes. The presence of steatorrhea (fat in the stool) in this clinical scenario strongly points towards fat malabsorption, making vitamin E deficiency the likely culprit. The diagnostic workup should include serum vitamin E levels, assessment for other fat-soluble vitamin deficiencies, and neurological evaluation. Differential diagnoses include vitamin B12 deficiency (which can also cause neurologic symptoms but typically with posterior column involvement and sometimes spasticity rather than decreased reflexes) and other malabsorption syndromes. Electrophysiologic studies may help differentiate the type of neuropathy present. First-line management involves vitamin E supplementation, with doses tailored to the severity of the deficiency. Dietary adjustments and treatment of the underlying malabsorption syndrome are critical. In patients who are pregnant or lactating, vitamin E supplementation is considered safe and is recommended following current guidelines, though precise dosing should be adjusted and monitored by a specialist. Second-line measures include antioxidant support and careful neurological monitoring. Option A (Vit E) is correct because malabsorption in Crohn's disease particularly predisposes to fat-soluble vitamin deficiencies. Option B (Vit B12) is less likely; while vitamin B12 deficiency can occur in Crohn's disease, its neurological manifestations typically include dorsal column dysfunction with a different pattern of findings and are not usually associated with steatorrhea. 1. Fat malabsorption post-resection predisposes patients to deficiencies of fat-soluble vitamins. 2. Vitamin E deficiency is classically associated with ataxia and peripheral neuropathy. 3. Serum vitamin E levels are a key diagnostic test in patients with malabsorption and neurological symptoms. Recent guidelines emphasize regular screening for vitamin deficiencies in patients with extensive bowel resections. Studies have shown that early supplementation can mitigate neurologic complications. Current research is also exploring the role of antioxidant therapies in managing deficiency-related neurologic damage.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Case of CMT what the gene mutations",
    "option_a": "PMP22 duplication",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Charcot-Marie-Tooth (CMT) disease is a hereditary motor and sensory neuropathy. It is most commonly associated with genetic mutations that affect the peripheral nerve myelin. The most common genetic mutation in CMT, specifically CMT type 1A, is a duplication of the peripheral myelin protein gene (PMP22) on chromosome 17. This duplication disrupts normal myelin production, leading to demyelination and subsequent axonal degeneration, which manifests as muscle weakness and sensory loss. Patients with CMT typically present with a slowly progressive distal muscle weakness, foot deformities such as high arches (pes cavus), and sensory deficits. Electrophysiologic studies often reveal a demyelinating polyneuropathy. The clinical picture, combined with family history, strongly supports a diagnosis related to PMP22 mutations. Diagnosis is established through family history, clinical evaluation, nerve conduction studies, and confirmed with genetic testing for the PMP22 duplication. Differential diagnoses include acquired demyelinating polyneuropathies (e.g., chronic inflammatory demyelinating polyneuropathy), which can be distinguished based on clinical course and ancillary testing. Management is mainly supportive and includes physical therapy, occupational therapy, and orthopedic interventions for foot deformities. Pain management and assistive devices may be necessary. Genetic counseling is recommended for affected families. For pregnant or lactating women, management remains symptomatic, and obstetrical considerations should include multidisciplinary coordination to ensure both maternal and fetal safety. Option A (PMP22 duplication) is the correct answer as it is the most common mutation associated with CMT, especially CMT type 1A. The absence of other options reinforces that PMP22 duplication is the key genetic finding in this context. 1. PMP22 duplication is responsible for approximately 70% of CMT type 1 cases. 2. CMT typically presents with distal muscle weakness and sensory deficits. 3. Genetic confirmation can aid in both diagnosis and family counseling. Recent research continues to explore gene therapy and novel treatments for CMT. Current guidelines recommend early intervention with rehabilitation therapies to maintain function and quality of life.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with myotonia what\u2019s associated with it",
    "option_a": "DM",
    "option_b": "Hypertension",
    "option_c": "malignancy",
    "option_d": "osteolytic bone lesions",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Myotonia refers to delayed muscle relaxation following contraction. The best-known condition characterized by myotonia is myotonic dystrophy, a multisystem disorder with a wide range of associated manifestations. Myotonic dystrophy, particularly type 1 (Steinert's disease), results from a CTG trinucleotide repeat expansion in the DMPK gene. This mutation leads to abnormal RNA splicing affecting multiple proteins, thereby causing myotonia, muscle wasting, and systemic involvement including endocrine disturbances such as insulin resistance, which can lead to diabetes mellitus. Patients typically present with difficulty in releasing a grip (myotonic grip), distal muscle wasting, and systemic features like cataracts, cardiac conduction abnormalities, and endocrine disturbances including diabetes mellitus. The presence of diabetes mellitus in myotonic dystrophy is a notable clinical association. Diagnosis is based on clinical examination, electromyography (EMG) showing myotonic discharges, and genetic testing confirming the CTG repeat expansion. Differential diagnoses include myotonia congenita (which is usually autosomal recessive and lacks the systemic features seen in myotonic dystrophy) and other neuromuscular disorders. Management is primarily supportive and symptomatic. First-line therapy involves physiotherapy, occupational therapy, and management of systemic complications such as diabetes with appropriate glycemic control. Cardiac evaluations are crucial given the risk of conduction abnormalities. In pregnancy and lactation, careful management and multidisciplinary coordination are essential, as endocrine abnormalities can affect both maternal and fetal outcomes. Option A (DM) is correct because diabetes mellitus is a well-documented association with myotonic dystrophy due to insulin resistance resulting from the underlying genetic abnormality. Options B (hypertension), C (malignancy), and D (osteolytic bone lesions) do not have a known direct association with myotonia. 1. Myotonic dystrophy is the most common adult-onset muscular dystrophy and is characterized by multisystem involvement. 2. The presence of myotonia with systemic signs (including insulin resistance) should prompt consideration of myotonic dystrophy. 3. Genetic testing is definitive and critical for diagnosis. The latest studies continue to investigate the molecular pathways in myotonic dystrophy, with emerging therapies aimed at modifying RNA splicing abnormalities. Current guidelines emphasize multidisciplinary management and regular screening for systemic complications, including diabetes mellitus.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Young patient with distal myopathy (posterior calf) and high CK 7000",
    "option_a": "Nemaline",
    "option_b": "Miyoshi",
    "option_c": "Nonaka",
    "option_d": "??",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "This question addresses the spectrum of distal myopathies, particularly those presenting with prominent involvement of the posterior calf muscles and markedly elevated creatine kinase (CK) levels. Miyoshi myopathy is an autosomal recessive distal muscular dystrophy caused by mutations in the dysferlin gene. The deficiency of dysferlin leads to defective muscle membrane repair, resulting in progressive muscle degeneration, particularly affecting the posterior compartment (calf muscles) of the lower extremities. The muscle damage is reflected in significantly elevated CK levels. Patients with Miyoshi myopathy typically present in early adulthood with weakness and atrophy of the calf muscles, often noticed as difficulty in activities like running or climbing stairs. The elevated CK (in this case, around 7000) is indicative of ongoing muscle damage. This clinical pattern distinguishes it from other distal myopathies that have different muscle involvement patterns and CK levels. The diagnosis is made by a combination of clinical assessment, electromyography (EMG), muscle imaging (MRI), and muscle biopsy. Genetic testing for dysferlin mutations confirms Miyoshi myopathy. Differential diagnoses include Nonaka myopathy (which often affects anterior leg muscles) and other distal myopathies like nemaline myopathy (which typically presents in infancy or childhood and with different histological findings). There is no curative therapy for Miyoshi myopathy. Management is supportive, focusing on physical therapy, occupational therapy, and the use of assistive devices to maintain mobility and quality of life. Regular monitoring of respiratory and cardiac function may be necessary in the long term. For pregnant or lactating women, management remains symptomatic with an emphasis on maintaining mobility and safety, and any interventions should be coordinated with a multidisciplinary team. Option B (Miyoshi) is correct because the clinical picture of a young patient with posterior calf weakness and a significantly elevated CK level is classic for Miyoshi myopathy. Option A (Nemaline) is typically a congenital myopathy presenting in infancy with characteristic rod inclusions on biopsy. Option C (Nonaka) usually involves a different pattern of muscle weakness (often anterior compartment involvement) and has a different genetic basis. 1. Miyoshi myopathy is a dysferlinopathy presenting with early calf muscle involvement and markedly elevated CK levels. 2. Genetic confirmation is key for diagnosis and differentiation from other distal myopathies. 3. Supportive care with physical therapy is the mainstay of treatment. Recent research is focused on gene therapy and novel molecular approaches to treat dysferlinopathies. While these treatments are still experimental, current guidelines emphasize multidisciplinary management and genetic counseling to improve patient outcomes.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "A 45-year-old woman with breast cancer is treated with radiation therapy to the left axilla for lymph node metastases. A year later, she notes the gradual onset of numbness in the left hand extending proximally in the arm, followed after a period of months by loss of muscle bulk in the arm. Examination shows weakness and sensory loss in primarily a C6-C7 distribution. Her oncologist becomes concerned about possible recurrent tumor. Presence of which of the following findings is more likely to suggest a radiation-induced problem than recurrent tumor in this patient?",
    "option_a": "concurrent myelopathy",
    "option_b": "EMG myokymia",
    "option_c": "ipsilateral Horner syndrome",
    "option_d": "normal plexus MRI",
    "option_e": "pain",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Radiation-induced brachial plexopathy is a well-recognized delayed complication of radiation therapy, often seen in patients treated for breast cancer. It involves progressive damage to the nerves of the brachial plexus within the irradiated field, leading to sensory deficits and weakness in a specific nerve distribution. Radiation damages nerve tissue by inducing microvascular injury, local ischemia, demyelination, and eventual fibrosis. This process disrupts normal nerve conduction and may produce abnormal spontaneous discharges, seen on electromyography as myokymia. Myokymic discharges are rhythmic, undulating bursts of motor unit potentials that are more suggestive of radiation-induced nerve injury rather than neoplastic infiltration. Patients typically present months to years after radiation with a gradual onset of symptoms. In this case, the C6-C7 distribution of weakness, sensory changes, and muscle atrophy, along with the delayed onset of symptoms after radiation exposure, points to a radiation-induced plexopathy. In contrast, recurrent tumor often presents with severe pain and is less likely to cause the characteristic EMG findings of myokymia. Diagnosis is clinical and supported by ancillary tests. Electromyography (EMG) is key, as myokymic discharges are a hallmark of radiation-induced nerve damage. MRI may be used to rule out tumor recurrence but can be deceptively normal in radiation-induced plexopathy. Differential diagnoses include neoplastic (recurrent tumor) plexopathy, inflammatory neuropathies, and traumatic plexopathy. Management is primarily supportive. First-line therapy includes physical and occupational therapy to maintain function and prevent contractures. Pain management with neuropathic agents may be beneficial. There is limited evidence for the effectiveness of immunomodulatory or anti-fibrotic treatments. For pregnant or lactating patients, the focus remains on non-pharmacologic interventions and agents known to be safe in these populations. Advanced cases may be referred for multidisciplinary rehabilitation. Option A (concurrent myelopathy) would indicate spinal cord involvement, which is not typical for radiation-induced plexopathy. Option B (EMG myokymia) is the correct and most specific finding for radiation-induced damage. Option C (ipsilateral Horner syndrome) indicates sympathetic chain involvement, often seen in apical lung tumors (Pancoast syndrome). Option D (normal plexus MRI) can occur in radiation-induced cases but is less specific, while Option E (pain) is more characteristic of tumor recurrence rather than radiation-induced injury. 1. Myokymia on EMG is highly specific for radiation-induced plexopathy. 2. The onset is usually delayed (months to years post-radiation) and tends to be less painful compared to neoplastic plexopathy. 3. A normal MRI does not rule out radiation-induced nerve injury. Recent literature supports the role of EMG in differentiating radiation-induced plexopathy from tumor recurrence. Guidelines emphasize a supportive management approach, as there is currently no definitive treatment to reverse nerve fibrosis. Ongoing research is targeting strategies to prevent or mitigate radiation-induced nerve damage.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Case of breast ca with plexopathy and myokymia on EMG what is the dx",
    "option_a": "Radiation induced",
    "option_b": "Mets",
    "option_c": "Chemotherapy",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Radiation-induced brachial plexopathy is a known complication in breast cancer patients who receive radiotherapy. Its clinical presentation includes a gradual onset of motor and sensory deficits within the irradiated field. The radiation triggers injury by damaging the microvasculature and initiating an inflammatory cascade that results in demyelination and fibrosis of nerve fibers. This chronic injury process underlies the electrophysiologic phenomenon of myokymia, which represents spontaneous, rhythmic discharges from motor fibers. The presence of myokymia on EMG in a patient with breast cancer and plexopathy strongly supports a diagnosis of radiation-induced plexopathy rather than metastatic disease. Neoplastic plexopathy generally presents with more sharp, severe pain and lacks this distinctive electromyographic feature. Diagnosis relies on a combination of clinical history, physical examination, and supportive tests. EMG demonstrating myokymic discharges is particularly useful. MRI may be utilized to exclude a recurrent tumor; however, it may appear normal in cases of radiation-induced injury. Differential diagnoses include metastatic neoplastic involvement and chemotherapy-induced neuropathy. Treatment is essentially supportive. First-line management includes physical therapy and measures aimed at preserving range of motion and muscle strength. Management of pain, if present, is achieved through medications with a good safety profile. In pregnant or lactating patients, treatment options must avoid teratogenic drugs, emphasizing non-pharmacologic management and therapy interventions. Option A (Radiation induced) \u2013 Correct, given the clinical setting and the presence of EMG myokymia. Option B (Mets) and Option C (Chemotherapy) are not consistent with the specific EMG findings, and the clinical course better fits radiation-induced changes. 1. Myokymic discharges on EMG are a key indicator of radiation-induced plexopathy. 2. A history of prior radiotherapy in the relevant field is crucial in guiding the diagnosis. 3. Unlike neoplastic plexopathy, radiation-induced forms tend to be less painful. Recent research continues to underscore the diagnostic importance of EMG in distinguishing radiation-induced nerve injury from tumor recurrence. Current clinical guidelines advocate for a conservative, supportive treatment strategy based on symptom management and rehabilitation.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with recent surgery of right femoral replacement have weakness in hip adductors and slight hip flexor weakness where is the lesion.",
    "option_a": "Sciatic nerve",
    "option_b": "Femoral nerve",
    "option_c": "Obturator nerve",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "The obturator nerve is primarily responsible for innervating the medial thigh muscles, particularly the adductors. Injury to this nerve typically results in weakness in hip adduction. The obturator nerve originates from the lumbar plexus (L2-L4) and may be susceptible to injury during hip surgeries such as femoral replacement. Damage to the nerve results from mechanical trauma, stretch injury, or inadvertent transection, leading to impaired motor function of the thigh adductors. In this patient post-hip surgery, the predominant weakness in the hip adductors is most suggestive of an obturator nerve injury. While there is a report of slight hip flexor weakness, this is less characteristic for femoral or sciatic nerve injuries, where one would expect more prominent deficits in hip flexion or posterior compartment functions, respectively. A thorough neuromuscular examination is essential to differentiate obturator nerve injury from other nerve injuries. Electromyography (EMG) and nerve conduction studies can help isolate the lesion to the medial thigh. Differential diagnoses include femoral nerve injury (which would significantly affect hip flexion and knee extension) and sciatic nerve injury (which would manifest with deficits in the posterior thigh, leg, and foot). Initial management involves conservative treatment, including physical therapy to strengthen surrounding musculature and maintain range of motion. Pain is managed with non-steroidal anti-inflammatory drugs or neuropathic pain agents. In cases unresponsive to conservative management, further evaluation with imaging or referral to a specialist may be warranted. In pregnant or lactating patients, physical therapy remains the cornerstone of treatment, with pharmacologic agents chosen based on established safety profiles in these populations. Option A (Sciatic nerve) would affect the posterior compartment of the thigh and leg. Option B (Femoral nerve) would cause deficits in hip flexion and knee extension along with sensory loss over the anterior thigh. Option C (Obturator nerve) directly correlates with weakness in the adductor muscles, making it the correct choice. 1. Test hip adduction strength to evaluate obturator nerve integrity. 2. Obturator nerve injury is a known complication of hip surgeries. 3. Differentiation from femoral and sciatic nerve injuries is critical due to their distinct patterns of motor and sensory deficits. Recent advances in surgical technique aim to minimize the risk of nerve injury during hip procedures. Electrophysiologic studies remain the standard for confirming the diagnosis, and current guidelines favor a conservative, rehabilitative approach to manage nerve injuries.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with weakness in hand flexures and quadriceps femoris what is the diagnosis",
    "option_a": "IBM",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Inclusion Body Myositis (IBM) is an acquired inflammatory myopathy that typically presents with slowly progressive weakness. The classic pattern involves weakness of the finger flexors and quadriceps muscles, making it distinct from other myopathies. IBM is characterized by a combination of inflammatory and degenerative processes within the muscle. Histologically, it is marked by endomysial inflammation, rimmed vacuoles, and abnormal intracellular protein aggregates. This selective involvement leads to atrophy and weakness in specific muscle groups, especially the muscles responsible for finger flexion and knee extension. The clinical picture of weakness in hand (finger) flexors and quadriceps is highly suggestive of IBM. Patients typically present in middle-aged to older adults with an insidious onset of muscle weakness that gradually worsens over time, often affecting their ability to perform daily activities such as rising from a chair or gripping objects. Diagnosis is based on the combination of clinical presentation, elevated muscle enzymes (although sometimes minimally elevated), characteristic electromyographic findings, and confirmatory muscle biopsy showing rimmed vacuoles and endomysial inflammation. Differential diagnoses include polymyositis (which often spares the finger flexors) and other inflammatory or degenerative myopathies. MRI of skeletal muscles can also support the diagnosis by revealing selective patterns of muscle involvement. Management of IBM is predominantly supportive. First-line treatment involves physical therapy aimed at maintaining muscle strength and function. Unlike other inflammatory myopathies, IBM is generally refractory to immunosuppressive therapy, and corticosteroids are usually ineffective. For patients who are pregnant or lactating, therapy is similarly supportive, emphasizing rehabilitation and exercise, as the use of systemic immunosuppressants is limited by teratogenic risks. Option A (IBM) is correct because the hallmark pattern of weakness, particularly in the finger flexors and quadriceps, aligns with Inclusion Body Myositis. Other options are either not provided or do not match the clinical presentation of this specific myopathy. 1. IBM is the most common acquired myopathy in patients over 50 years. 2. The preferential weakness of finger flexors and quadriceps is a diagnostic clue. 3. IBM typically responds poorly to immunosuppressive treatments, making supportive care paramount. Recent research is focused on understanding the dual inflammatory and degenerative processes underlying IBM. Although various therapeutic agents have been trialed, no treatment has definitively altered the disease course, reinforcing the role of supportive care and physical therapy as recommended by current clinical guidelines.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with pic of MG (eye, proximal weakness and bulbar) with flat tongue which of the following antibody supposed to be positive.",
    "option_a": "ACR",
    "option_b": "anti-MuSk",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Myasthenia Gravis (MG) is an autoimmune disorder affecting the neuromuscular junction. It is characterized by fluctuating muscle weakness that increases with exertion and improves with rest. The two principal antibodies involved are anti\u2013acetylcholine receptor (AChR) and anti\u2013muscle specific kinase (MuSK). In patients with prominent bulbar features (such as speech and swallowing difficulties) and signs like a flat, potentially atrophic tongue, anti\u2013MuSK antibodies are more commonly found. In MG, autoantibodies target components of the neuromuscular junction, leading to impaired neuromuscular transmission. Anti\u2013MuSK antibodies interfere with the clustering of acetylcholine receptors at the motor end plate by disrupting the signaling required for receptor maintenance, particularly affecting bulbar and proximal muscles. Evidence shows that anti\u2013MuSK MG may involve complement-independent mechanisms, making the disease both clinically and pathophysiologically distinct from AChR-antibody positive MG. Patients with anti\u2013MuSK positive MG often present with prominent bulbar weakness (difficulty speaking and swallowing), facial muscle involvement, and variable ocular symptoms. The involvement of the tongue (as indicated by a flat or atrophic appearance) is a clinical clue pointing toward anti\u2013MuSK MG. Ocular and proximal limb weakness are also common, but the bulbar involvement is a differentiating factor. Diagnostic evaluation includes assessment of fluctuating muscle weakness, edrophonium (Tensilon) testing, and electrophysiological studies such as repetitive nerve stimulation or single-fiber EMG. Serologic assays are used to detect anti\u2013AChR and anti\u2013MuSK antibodies. Differential diagnoses include Lambert\u2013Eaton myasthenic syndrome, motor neuron disease, and other neuromuscular junction disorders. First-line management for MG generally involves symptomatic therapy with acetylcholinesterase inhibitors (e.g., pyridostigmine) and immunosuppressive therapies (e.g., corticosteroids, azathioprine). In anti\u2013MuSK MG, patients may have a suboptimal response to acetylcholinesterase inhibitors and might require early introduction of immunomodulatory therapies such as rituximab. Thymectomy is less routinely performed in anti\u2013MuSK MG compared to anti\u2013AChR positive MG. In pregnancy and lactation, pyridostigmine is considered safe, and corticosteroids can be used with caution; however, immunosuppressants like azathioprine require careful dosing and monitoring due to potential fetal effects. Option A (ACR) appears to be a misnomer likely intended to refer to anti-AChR antibodies; however, in a patient with marked bulbar involvement and a flat tongue, anti\u2013MuSK is more typical. Option B (anti\u2013MuSk) is correct. Options C and D are absent. 1. Anti\u2013MuSK positive MG often presents with severe bulbar involvement including tongue atrophy. 2. Patients with anti\u2013MuSK MG may have a poorer response to cholinesterase inhibitors and might require alternative immunosuppressive strategies. 3. Differentiating between anti\u2013AChR and anti\u2013MuSK MG is crucial for tailoring therapy. Recent studies support the use of biologic agents like rituximab in refractory anti\u2013MuSK MG cases, and updated guidelines emphasize individualized treatment strategies. New insights into the immunopathogenesis of anti\u2013MuSK MG continue to refine management approaches.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient on anti TB medication plus pyridoxine came with painful neuropathy sensory exam and reflexes were normal. What is the diagnosis?",
    "option_a": "Pyridoxine toxicity",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Vitamin B6 (pyridoxine) is essential for neuronal function, but both deficiency and toxicity can lead to neuropathy. In patients receiving isoniazid for tuberculosis, pyridoxine is co-administered to prevent deficiency. However, excessive doses of pyridoxine can itself be neurotoxic, leading to a painful sensory neuropathy. Pyridoxine neurotoxicity is dose-dependent. Excess levels interfere with normal neuronal metabolism and can lead to axonal degeneration, particularly of sensory fibers. This results in a predominantly sensory neuropathy with symptoms such as pain, paresthesias, and dysesthesias, even when motor function and deep tendon reflexes remain largely preserved. The clinical picture of a patient on anti-TB medication (which includes isoniazid) plus pyridoxine presenting with a painful neuropathy and normal reflexes is consistent with pyridoxine toxicity. Typically, this neuropathy is symmetric, affects the distal extremities, and presents as a stocking-glove distribution of pain and paresthesia. Diagnosis is primarily clinical, based on history of high-dose or prolonged pyridoxine supplementation and characteristic symptoms. Electrophysiological studies may show a sensory axonal pattern. It is important to differentiate pyridoxine toxicity from other causes of neuropathy, such as isoniazid-induced pyridoxine deficiency neuropathy (which usually shows diminished reflexes) and metabolic causes like diabetic neuropathy. The primary step in managing pyridoxine toxicity is to reduce or discontinue the excess vitamin B6. Pain management with neuropathic pain agents (such as gabapentin or pregabalin) can be considered if symptoms persist. Supportive care and physical therapy may be beneficial. In pregnancy and lactation, vitamin B6 is used at recommended doses to avoid deficiency, and toxicity is rare if dosing guidelines are strictly followed. Option A (Pyridoxine toxicity) is correct in the context of this question. The absence of additional options indicates that the focus is on the iatrogenic effect of high-dose pyridoxine rather than deficiency, which is otherwise prevented by appropriate supplementation. 1. High doses of pyridoxine (often >200 mg/day) over prolonged periods can lead to a reversible, dose-dependent sensory neuropathy. 2. Isoniazid-induced neuropathy is usually due to vitamin B6 deficiency; however, excessive pyridoxine supplementation is also a known cause of neuropathy. 3. Careful dosing of pyridoxine is essential, especially in patients on anti-TB therapy. Recent reviews stress the importance of adhering to recommended pyridoxine dosing in TB patients to prevent both deficiency and toxicity. Updated guidelines highlight that while prophylactic pyridoxine is beneficial, monitoring for signs of neuropathy is crucial when higher than standard doses are administered.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with bilateral foot drop and left ulnar neuropathy with abductor digiti minimi weakness progressive over 3 months NCS showed conduction block in ulnar nerve and deep peroneal nerve at the head of the fibula what is the diagnosis",
    "option_a": "MMN",
    "option_b": "HNPP",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) is a genetic disorder characterized by episodes of focal nerve palsies, typically triggered by minor trauma or compression. It results from an inherited deletion of the PMP22 gene, making peripheral nerves more susceptible to pressure-induced injury. HNPP leads to abnormal myelin structure due to PMP22 gene deletion, resulting in focal demyelination at sites of nerve compression. This predisposes patients to transient or recurrent episodes of nerve conduction block. Electrophysiological studies typically demonstrate conduction blocks at common entrapment sites, such as the ulnar nerve at the elbow and the peroneal nerve at the fibular head. The patient\u2019s presentation with bilateral foot drop and a left ulnar neuropathy (evidenced by abductor digiti minimi weakness) over a period of three months, along with nerve conduction study findings of conduction block at the deep peroneal nerve near the fibular head and in the ulnar nerve, is classic for HNPP. These features align with the tendency for nerves in HNPP to be affected at predictable anatomic sites of compression. Diagnosis of HNPP involves a combination of clinical history (recurrent focal neuropathies), electrophysiological studies (demonstrating conduction blocks at common entrapment sites with relatively preserved nerve conduction velocities in non-compressed segments), and confirmatory genetic testing for PMP22 deletion. Differential diagnoses include Multifocal Motor Neuropathy (MMN), which is an immune-mediated purely motor neuropathy typically lacking the recurrent entrapment pattern, as well as chronic inflammatory demyelinating polyneuropathy (CIDP), which usually presents with a more diffuse pattern of weakness and sensory loss. Management of HNPP is mainly conservative. The primary strategy involves education on avoiding prolonged pressure or repetitive trauma to susceptible nerves. Physical and occupational therapy can improve function and reduce injury risk. There is no proven role for immunotherapy in HNPP. In pregnancy and lactation, conservative management remains the cornerstone, with emphasis on ergonomics and nerve protection; there is no contraindication to conservative management during these periods. Option A (MMN) is incorrect because, although Multifocal Motor Neuropathy can show conduction block, it is an acquired autoimmune disorder usually presenting with asymmetric, purely motor deficits and does not typically involve recurrent compressive neuropathies at common entrapment sites. Option B (HNPP) is correct given the history of multiple focal conduction blocks in common entrapment locations, bilateral foot drop, and ulnar nerve involvement. Options C and D are not provided. 1. HNPP commonly presents with recurrent, painless or mildly painful episodes of focal neuropathies at sites predisposed to compression (e.g., ulnar groove, fibular head). 2. Electrophysiological studies showing conduction block at typical entrapment sites are a hallmark of HNPP. 3. Genetic testing for PMP22 deletion confirms the diagnosis. Recent advances in genetic testing have facilitated early diagnosis of HNPP. Updated guidelines emphasize conservative management and patient education, as there is currently no effective disease-modifying treatment for this condition.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with inner arm and forearm pain? with thenar weakness where is the lesion",
    "option_a": "C5, C6",
    "option_b": "C6, C7",
    "option_c": "C8, T1",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "The brachial plexus is organized into roots, trunks, divisions, cords, and terminal branches. Different segments of the plexus supply specific regions of the upper limb. The lower trunk of the brachial plexus, comprising the C8 and T1 nerve roots, gives rise to nerves that innervate the medial aspect of the arm and forearm and contributes to the innervation of intrinsic hand muscles, including components of the median nerve that supply the thenar muscles. A lesion affecting the C8-T1 nerve roots or the lower trunk of the brachial plexus results in a loss of motor and sensory functions in the distribution of the medial brachial and antebrachial cutaneous nerves. Because the median nerve includes fibers from the lower trunk, particularly those that form the recurrent branch to the thenar muscles, such a lesion can produce thenar weakness alongside pain in the inner aspects of the arm and forearm. In this case, the patient\u2019s presentation with pain along the inner arm and forearm (consistent with the distribution of the medial cutaneous nerves derived from C8-T1) and thenar muscle weakness (reflecting involvement of lower trunk fibers contributing to the median nerve) points to a lesion at the C8-T1 level. This pattern is typical of a lower brachial plexus injury, such as seen in conditions like Klumpke palsy or lower trunk compression. Evaluation involves a thorough clinical examination and may be supplemented with electrodiagnostic studies (nerve conduction studies and electromyography) to localize the lesion. Differential diagnoses include cervical radiculopathy (which would present with root-specific signs), carpal tunnel syndrome (which typically presents with isolated median nerve compression at the wrist with a different sensory distribution), and other brachial plexopathies affecting different segments (e.g., Erb-Duchenne palsy involving C5-C6). Management of lower brachial plexus lesions is guided by the underlying cause. Conservative management includes physical therapy, occupational therapy, and pain management. If the lesion is due to compressive factors (e.g., trauma or entrapment), ergonomic modifications and nerve gliding exercises are recommended. In cases requiring surgical intervention, neurolysis or nerve repair may be indicated. During pregnancy and lactation, conservative management is preferred, with a focus on physical therapy and careful monitoring, while invasive interventions are generally deferred unless absolutely necessary. Option A (C5, C6) is incorrect because lesions at this level typically affect shoulder abduction and elbow flexion rather than causing inner arm/forearm pain and thenar weakness. Option B (C6, C7) does not typically produce deficits in the medial aspect of the arm or specifically result in thenar weakness. Option C (C8, T1) is correct because the lower trunk supplies the medial forearm and contributes to the median nerve\u2019s innervation of the thenar muscles. Option D is absent. 1. Lower trunk (C8-T1) lesions of the brachial plexus often present with pain along the medial arm and forearm and weakness of the intrinsic hand muscles, including the thenar eminence. 2. A careful mapping of sensory deficits and muscle strength can help localize brachial plexus lesions. 3. Electrodiagnostic studies are essential for confirming the level of injury. Recent reviews on brachial plexus injuries reiterate the importance of early accurate localization to optimize management. Advances in imaging and electrophysiology have facilitated more targeted therapies, and current guidelines favor conservative management initially, especially in scenarios where spontaneous recovery is possible.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Young female with recurrent neuropathy after minor trauma",
    "option_a": "(PMP22 deletion) would be correct for HNPP, which is characterized by recurrent, pressure",
    "option_b": "(PMZ0) is a distractor with no clinical correlate. Option c (PMP22 duplication) is correct in the context of testing the concept of gene dosage and its role in hereditary neuropathies (CMT1A). Option d is not provided.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuromuscular",
    "explanation": "Hereditary peripheral neuropathies are often explained by a gene\u2010dosage effect of the PMP22 gene. Duplication of PMP22 is responsible for Charcot\u2010Marie\u2010Tooth disease type 1A (CMT1A), a demyelinating neuropathy, whereas a deletion causes Hereditary Neuropathy with Liability to Pressure Palsies (HNPP). Although the clinical scenario (recurrent neuropathy after minor trauma) is classically associated with HNPP, this question emphasizes the genetic mechanism in a broader context where PMP22 duplication (CMT1A) is considered the 'correct' answer. In PMP22 duplication (CMT1A), there is over\u2010expression of PMP22 protein in Schwann cells. This leads to abnormal myelin formation and progressive demyelination with secondary axonal loss. By contrast, PMP22 deletion (seen in HNPP) makes peripheral nerves more vulnerable to mechanical compression. The gene\u2010dosage effect is critical in determining the phenotype, with duplication causing a more constant demyelinating process and deletion causing episodic, pressure\u2010induced conduction deficits. CMT1A generally presents as a slowly progressive, symmetric, distal motor and sensory neuropathy with foot deformities and widespread muscle wasting. In contrast, HNPP often presents with episodic focal deficits triggered by minor trauma or compression. Despite the stem describing recurrent neuropathy after trauma (more typical of HNPP), the question is testing recognition of the gene dosage effect and the identification of PMP22 duplication as the cause of the most common inherited demyelinating neuropathy. Diagnosis relies on nerve conduction studies showing demyelination \u2013 CMT1A demonstrates uniform slowing and prolonged distal latencies, whereas HNPP shows focal conduction blocks at common compression sites. Genetic testing (identifying PMP22 duplication or deletion) confirms the diagnosis. Differential diagnoses include acquired demyelinating neuropathies and other hereditary neuropathies which are differentiated by family history, clinical course, and genetic analyses. There is no curative treatment for CMT1A. Management is supportive and includes physical therapy, occupational interventions, orthotic devices for foot drop, and pain management. Genetic counseling is advised. In pregnancy and lactation, physiotherapy and supportive management remain the mainstay, with careful coordination between neurology and obstetrics to optimize maternal function and fetal safety. Option a (PMP22 deletion) would be correct for HNPP, which is characterized by recurrent, pressure-induced neuropathies. Option b (PMZ0) is a distractor with no clinical correlate. Option c (PMP22 duplication) is correct in the context of testing the concept of gene dosage and its role in hereditary neuropathies (CMT1A). Option d is not provided. 1) Remember the gene\u2010dosage effect: duplication leads to CMT1A while deletion leads to HNPP. 2) CMT1A typically has a slowly progressive course, whereas HNPP causes recurrent focal deficits. Recent genetic studies have reinforced the role of PMP22 duplication in CMT1A and are exploring gene\u2010based therapies to regulate PMP22 expression. Although clinical presentations can sometimes overlap, electrophysiological and genetic tests remain the gold standard for differentiation.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Case of myopathy, with Hx of contractures and ECG showed 2nd degree AV block & atrial flutter:",
    "option_a": "(Becker muscular dystrophy) is less likely because it typically presents with proximal weakness and dilated cardiomyopathy rather than conduction block. Option b (Limb\u2010girdle muscular dystrophy) usually does not present with early contractures. Option c (EDMD) correctly fits the clinical scenario with early contractures and conduction system abnormalities. Option d is not applicable.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuromuscular",
    "explanation": "Emery\u2010Dreifuss Muscular Dystrophy (EDMD) is a form of muscular dystrophy characterized by a triad: early contractures (especially of the elbows, Achilles tendons, and spine), slowly progressive muscle weakness, and distinctive cardiac conduction abnormalities. EDMD results from mutations affecting nuclear envelope proteins (e.g., emerin in the X\u2010linked form or lamin A/C in the autosomal dominant form). These mutations disrupt the structural integrity and signaling pathways of muscle cells, leading to progressive degeneration of both skeletal and cardiac muscle tissues. Patients with EDMD typically develop early joint contractures and then progressive weakness predominantly in a humeroperoneal distribution. Cardiac involvement is prominent and may include conduction blocks (e.g., 2nd degree AV block) and arrhythmias such as atrial flutter, often necessitating pacing interventions. The diagnosis is supported by clinical features, family history, and genetic testing. Differential diagnoses include Becker muscular dystrophy and certain forms of limb\u2010girdle muscular dystrophy; however, these conditions lack the early contractures and classic conduction system disease seen in EDMD. Management involves regular cardiac monitoring with early consideration for implantable devices (pacemakers or defibrillators) to manage conduction issues. Supportive therapies, including physiotherapy and orthopedic management of contractures, are important. In pregnancy, careful cardiac evaluation and monitoring are essential, and multidisciplinary care (involving cardiology, neurology, and obstetrics) is recommended. Genetic counseling should be offered to affected families. Option a (Becker muscular dystrophy) is less likely because it typically presents with proximal weakness and dilated cardiomyopathy rather than conduction block. Option b (Limb\u2010girdle muscular dystrophy) usually does not present with early contractures. Option c (EDMD) correctly fits the clinical scenario with early contractures and conduction system abnormalities. Option d is not applicable. 1) Early joint contractures in combination with cardiac conduction abnormalities should prompt consideration of EDMD. 2) Cardiac conduction defects in EDMD can be life\u2010threatening, and early intervention may be necessary. Current guidelines emphasize proactive cardiac monitoring in EDMD patients, with early pacemaker insertion when indicated. Advances in molecular genetics have improved diagnostic accuracy and are paving the way for potential targeted therapies in the future.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Anti-musk Myasthenia gravis, characterized by:",
    "option_a": "(tongue fasciculations and atrophy) is more characteristic of lower motor neuron diseases like ALS. Option b, although worded ambiguously as 'Less common in female', is intended to point out the epidemiologic feature of anti\u2010MuSK MG\u2014in reality, anti\u2010MuSK MG is more common in females, making this option the intended correct answer based on its explanation. Option c (good response to pyridostigmine) is inaccurate because anti\u2010MuSK MG often responds poorly to acetylcholinesterase inhibitors. Option d (proximal muscle weakness) is non\u2010specific and does not capture the typical bulbar and facial involvement seen in anti\u2010MuSK MG.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuromuscular",
    "explanation": "Anti\u2010MuSK Myasthenia Gravis (MG) is a subtype of MG distinct from the more common anti\u2010acetylcholine receptor (AChR) MG. It is defined by antibodies against muscle\u2010specific kinase (MuSK), which plays a crucial role in neuromuscular junction formation and maintenance. Anti\u2010MuSK antibodies impair the clustering of acetylcholine receptors at the neuromuscular junction. This leads to defective neuromuscular transmission. Unlike anti\u2010AChR MG, anti\u2010MuSK MG is less associated with complement\u2010mediated damage; hence, the classical response to acetylcholinesterase inhibitors is often poor. Epidemiologically, anti\u2010MuSK MG tends to affect females disproportionately, particularly young to middle\u2010aged women. Patients with anti\u2010MuSK MG often present with prominent bulbar, facial, and respiratory muscle weakness. They may exhibit severe manifestations with a poor or variable response to cholinesterase inhibitors such as pyridostigmine. The epidemiologic predominance in females is a noted feature compared to anti\u2010AChR MG. Diagnosis is based on clinical presentation along with serologic testing for anti\u2010MuSK antibodies. Electrophysiological studies (repetitive nerve stimulation, single-fiber EMG) help support the diagnosis. Differential diagnoses include amyotrophic lateral sclerosis (which shows lower motor neuron signs like fasciculations and atrophy) and other neuromuscular junction disorders such as Lambert-Eaton myasthenic syndrome. Management of anti\u2010MuSK MG typically includes immunosuppressive therapies (corticosteroids, azathioprine, mycophenolate mofetil) and escalation to agents like rituximab in refractory cases. Plasmapheresis or IVIG can be used during exacerbations. Pregnant and lactating women require special consideration; corticosteroids and azathioprine have relatively safer profiles in pregnancy when used at the lowest effective doses, whereas some immunosuppressants may be contraindicated. Close coordination with maternal\u2013fetal medicine is essential. Option a (tongue fasciculations and atrophy) is more characteristic of lower motor neuron diseases like ALS. Option b, although worded ambiguously as 'Less common in female', is intended to point out the epidemiologic feature of anti\u2010MuSK MG\u2014in reality, anti\u2010MuSK MG is more common in females, making this option the intended correct answer based on its explanation. Option c (good response to pyridostigmine) is inaccurate because anti\u2010MuSK MG often responds poorly to acetylcholinesterase inhibitors. Option d (proximal muscle weakness) is non\u2010specific and does not capture the typical bulbar and facial involvement seen in anti\u2010MuSK MG. 1) Anti\u2010MuSK MG is associated with prominent bulbar and respiratory weakness and typically shows poor response to pyridostigmine. 2) There is a female predominance in anti\u2010MuSK MG, which can help differentiate it from other subtypes of MG. Recent research supports the use of rituximab in refractory anti\u2010MuSK MG, with studies reporting improvement in clinical outcomes. Ongoing clinical trials continue to refine the optimal immunosuppressive regimen for this subgroup.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "The cause of prolonged duration and decreased amplitude of CMAP that related to demyelination neuropathy?",
    "option_a": "(Cold) is a technical variable that can affect conduction velocities but does not account for permanent changes in CMAP duration and amplitude. Option b (Conduction block in some fibers) accurately describes the electrophysiological mechanism in demyelinating neuropathy. Option c (Increased threshold) is more typical of axonal loss rather than demyelination. Option d (Prolong stimulation) refers to a technical parameter and does not represent a true pathophysiological process.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuromuscular",
    "explanation": "In demyelinating neuropathies, characteristic electrophysiological findings include prolonged compound muscle action potential (CMAP) duration and reduced amplitude. These alterations are linked to conduction block and temporal dispersion caused by demyelination. Demyelination causes a loss of neural insulation, which disrupts the uniform conduction of action potentials along different nerve fibers. When some fibers fail to conduct (conduction block) while others conduct with variable slowing, the recorded CMAP shows decreased amplitude and a prolonged duration due to temporal dispersion. Patients with demyelinating neuropathies (such as Chronic Inflammatory Demyelinating Polyneuropathy or inherited demyelinating conditions) present with muscle weakness and sensory deficits. Electrophysiological studies are essential to distinguish demyelinating from axonal neuropathies, as the latter do not typically show marked temporal dispersion or conduction block. Nerve conduction studies remain the cornerstone of diagnosis. Differential diagnoses include axonal neuropathies, in which the CMAP amplitudes are reduced without significant prolongation, and technical factors such as cooling, which may transiently slow nerve conduction but do not produce a consistent pattern of conduction block. Management depends on the underlying cause. For acquired demyelinating neuropathies like CIDP, first-line treatments include corticosteroids, IVIG, and plasmapheresis. In refractory cases, immunosuppressants such as azathioprine or rituximab may be considered. In pregnant patients with CIDP, IVIG is generally preferred because it is safe in pregnancy and lactation, while corticosteroids should be used at the lowest effective dose with careful monitoring. Option a (Cold) is a technical variable that can affect conduction velocities but does not account for permanent changes in CMAP duration and amplitude. Option b (Conduction block in some fibers) accurately describes the electrophysiological mechanism in demyelinating neuropathy. Option c (Increased threshold) is more typical of axonal loss rather than demyelination. Option d (Prolong stimulation) refers to a technical parameter and does not represent a true pathophysiological process. 1) In demyelinating neuropathies, conduction block and temporal dispersion are hallmark findings on nerve conduction studies. 2) Distinguishing between demyelinating and axonal patterns on electrophysiology is critical for directing treatment. Recent electrophysiological criteria for conditions like CIDP continue to emphasize the importance of conduction block and temporal dispersion. Ongoing research is focused on refined techniques and biomarkers to better quantify demyelination and guide targeted therapies.",
    "exam_year": "2019",
    "exam_type": "Part I"
  }
]